Innovations in Automation—High-Throughput Dynamic Light Scattering for Screening Biotherapeutic Formulations

October 2, 2015
Daniel Some

Daniel Some, PhD, is director of marketing and principal scientist, at Wyatt Technology Corporation, 6300 Hollister Ave, Santa Barbara, CA 93117-3253.

,
Russell Burge

BioPharm International, BioPharm International-10-15-2015, Volume 2015 eBook, Issue 2

This article introduces the technology that powers automated HT–DLS and explores its practical applications in enhancing formulation stability investigations.

BioPharm International

eBooks Volume 28, Issue 14  

Assessing a drug candidate’s suitability during preformulation is essential to minimize the risk of costly downstream failure. Stability is a defining feature of biotherapeutic performance; measuring formulation stability during early-phase screening allows developers to make robust predictions of suitability for further development.    Read this article and other articles in

BioPharm International

's 2015

eBook.